News | August 09, 2025
Akums reports Q1 FY26 PAT at Rs. 65 Cr
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
During this quarter, the company achieved a key milestone of reaching 1,000 DCGI approvals
Launched in Thailand, the ASEAN hub, marking an early entry into the fast-growing combination therapy market (DPP-4 and SGLT-2 inhibitor combination) with strong potential for market leadership
The CEP certification for Metformin Hydrochloride aligns with the company's strategy to penetrate stringently regulated markets
Offers affordable, high-quality solutions for diabetes care
Akums Drugs & Pharmaceuticals has launched Dapagliflozin + Pioglitazone tablets, a dual-action therapy for diabetes management
Approval based on results from T2NOW, one of the largest paediatric type-2 diabetes Phase III trials to date
Funding round led by Sarissa Capital, includes Sun Pharma, Polaris Partners
The product basket increased to 1800 medicines and 285 Surgical Equipment
Farxiga is expected to have such a strong influence on the market due to the impressive results
This FDC has been launched under the brand name Zita-PioMet, and contains Teneligliptin (20 mg) + Pioglitazone (15 mg) + Metformin (500mg/1000mg) in a sustained release (SR) formulation
Subscribe To Our Newsletter & Stay Updated
